Autoimmune hepatitis and cirrhosis represent a serious pathological progression where the body’s own defense system becomes the main aggressor. In an optimal state of health, lymphocytes protect the liver from external viruses and toxins. However, this biological balance is broken when the immune system fails to recognize liver cells and begins to attack them persistently. This pathology is characterized by chronic inflammation that gradually destroys the functional tissue of the organ. Therefore, if the disease is not diagnosed and treated in time, the inflammatory process evolves toward the formation of fibrosis bridges. Consequently, cirrhosis is the final stage of this damage, where the liver’s architecture is replaced by irreversible hepatic scarring.
Moreover, autoimmune hepatitis usually presents with elevated levels of liver enzymes and specific antibodies in the blood. It is important to highlight that accumulated cellular damage prevents the liver from performing critical tasks such as albumin synthesis or blood coagulation. Nevertheless, many patients remain asymptomatic until cirrhosis is fully established and signs of liver failure appear. As a result, medical surveillance through biopsies or imaging tests is vital to monitor the progression of tissue damage. Furthermore, the transition from active inflammation to permanent fibrosis marks a significant turning point in the individual’s prognosis.
For this reason, treatment with immunosuppressive drugs is fundamental to stop the self-destruction of liver tissue. In view of this, the use of corticosteroids and azathioprine has become the gold standard for inducing disease remission. Due to the fact that these medications modulate the defensive response, the body has a real opportunity to stop or even reverse the damage in early stages. On the other hand, once cirrhosis is total, the medical focus shifts toward preventing complications such as portal hypertension. Accordingly, the patient’s health depends on strict adherence to the therapeutic scheme to avoid inflammatory relapses.
Finally, the comprehensive management of autoimmune hepatitis and cirrhosis seeks to preserve the organ’s residual function and improve overall survival. Although advanced scarring is difficult to reverse, medical science allows for stabilizing patients for several decades. In summary, understanding the molecular mechanisms of the immune attack is key to developing new and more selective therapies. Ultimately, the main goal is to normalize liver function tests and prevent the need for an organ transplant in the future. Lastly, education regarding the disease empowers the patient to identify warning symptoms immediately and effectively.